As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...

For tech companies, the healthcare vertical is now the fastest growing business. The US, which spends about $5 trillion on ...

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that ...

The potential impact of Trump’s suspension of Foreign Corrupt Practices Act (FCPA) enforcement is significant, particularly ...

Drugmaker Eli Lilly rose 4% after the company forecast annual profit largely above estimates, while Coach-parent Tapestry jumped 12.3% on annual sales and profit forecast raise. Philip Morris ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly and Co. shares climbed about 2% Thursday morning to $857.40 while broader trading indexes started the day mixed. Lilly's stock has already climbed 9% so far this year, as of Wednesday. Share ...